Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 18/20 | 0.45 |
| ▸ | RORC | P51449 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Crictibant SCHEMBL21001160 | 0.92 | BDKRB2 (0.56) | BDKRB2CYP3A4 | |
| Deucrictibant SCHEMBL21001161 | 0.92 | BDKRB2 (0.56) | BDKRB2CYP3A4 | |
| Deucrictibant SCHEMBL26634662 | 0.92 | BDKRB2 (0.56) | BDKRB2CYP3A4 | |
| Crictibant SCHEMBL30376379 | 0.92 | BDKRB2 (0.56) | BDKRB2CYP3A4 | |
| SCHEMBL21031777 | 0.91 | BDKRB2 (0.45) | BDKRB2RORCCYP3A4 | |
| SCHEMBL26634724 | 0.88 | BDKRB2 (0.56) | BDKRB2CYP3A4 | |
| SCHEMBL21030181 | 0.88 | BDKRB2 (0.46) | BDKRB2RORCCYP3A4 | |
| SCHEMBL21030527 | 0.86 | BDKRB2 (0.57) | BDKRB2CYP3A4 | |
| SCHEMBL24427017 | 0.86 | BDKRB2 (0.56) | BDKRB2CYP3A4 | |
| Deucrictibant SCHEMBL22320140 | 0.85 | BDKRB2 (0.54) | BDKRB2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820756-B2 | Bradykinin B2 receptor antagonists | Pharvaris Netherlands B.V. (NL) | 2023-11-21 | — | — | US | disclosed |
| US-11820756-B2 | Bradykinin B2 receptor antagonists | Pharvaris Netherlands B.V. (NL) | 2023-11-21 | — | — | US | disclosed |
| EP-3998259-A1 | NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS | Pharvaris Netherlands B.V. (NL) | 2022-05-18 | — | — | EP | disclosed |
| US-20220135543-A1 | NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS | Pharvaris Netherlands B.V. (NL) | 2022-05-05 | — | — | US | disclosed |
| EP-3713928-B1 | NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS | PHARVARIS NETHERLANDS B V (NL) | 2022-01-12 | — | — | EP | disclosed |
| US-20210017158-A1 | NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS | ANALYTICON DISCOVERY GMBH (DE) | 2021-01-21 | — | — | US | disclosed |
| US-10836748-B2 | Bradykinin B2 receptor antagonists | Pharvaris Netherlands B.V. (NL) | 2020-11-17 | — | — | US | disclosed |
| US-20200255405-A1 | NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS | ANALYTICON DISCOVERY GMBH (DE) | 2020-08-13 | — | — | US | disclosed |
| WO-2019101906-A1 | NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS | PHARVARIS B.V. (NL) | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017158-A1 | NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS | BDKRB2, BDKRB1, VIPR2 | BDKRB2 1/4885RORC 4082/4885CYP3A4 2143/4885 |
| US-20220135543-A1 | NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS | BDKRB2, BDKRB1, VIPR2 | BDKRB2 1/4885RORC 4082/4885CYP3A4 2143/4885 |
| US-10836748-B2 | Bradykinin B2 receptor antagonists | BDKRB2, BDKRB1, VIPR2 | BDKRB2 1/4885RORC 4230/4885CYP3A4 1840/4885 |
| US-11820756-B2 | Bradykinin B2 receptor antagonists | BDKRB2, BDKRB1, VIPR2 | BDKRB2 1/4885RORC 4230/4885CYP3A4 1840/4885 |
| US-20200255405-A1 | NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS | BDKRB2, BDKRB1, VIPR2 | BDKRB2 1/4885RORC 4082/4885CYP3A4 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.